4D Molecular Therapeutics FDMT Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's operating lease right-of-use assets in other assets?
- 4D Molecular Therapeutics (FDMT) reported operating lease right-of-use assets in other assets of $17.36M in Q1 2026.
- How has 4D Molecular Therapeutics's operating lease right-of-use assets in other assets changed year-over-year?
- 4D Molecular Therapeutics's operating lease right-of-use assets in other assets decreased by 14.8% year-over-year, from $20.37M to $17.36M.
- What is the long-term trend for 4D Molecular Therapeutics's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's operating lease right-of-use assets in other assets has grown at a 1.9% compound annual growth rate (CAGR), from $16.5M to $18.14M.